

Keytruda® (pembrolizumab) - New indication

- On September 18, 2024, <u>Merck announced</u> the FDA approval of <u>Keytruda (pembrolizumab)</u>, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
- Refer to the Keytruda drug label for a complete listing of all its other indications and usages.
- The approval of Keytruda for the new indication was based on KEYNOTE-483, a randomized, open-label, active-controlled study in 440 patients with unresectable advanced or metastatic MPM and no prior systemic therapy for advanced/metastatic disease. Patients were randomized to one of the following regimens: (1) Keytruda with pemetrexed and cisplatin or carboplatin on day 1 of each 21-day cycle for up to 6 cycles, followed by Keytruda every 3 weeks; or (2) pemetrexed and cisplatin or carboplatin on day 1 of each 21-day cycle for up to 6 cycles. The main outcome measure was overall survival (OS). Additional efficacy outcome measures were progression-free survival (PFS) and overall response rate (ORR).
 - Median OS was 17.3 months in the Keytruda arm vs. 16.1 months in the comparator arm (hazard ratio [HR] 0.79, 95% CI: 0.64, 0.98; p = 0.0162).
 - Median PFS was 7.1 months in the Keytruda arm vs. 7.1 months in the comparator arm (HR 0.80, 95% CI: 0.65, 0.99; p = 0.0194).
 - The ORR was 52% in the Keytruda arm vs. 29% in the comparator arm (p < 0.00001).
- The recommended dose of Keytruda for the treatment of MPM is 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion. Keytruda should be given until disease progression, unacceptable toxicity, or up to 24 months.
- Refer to the Keytruda drug label for dosing for all its other indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.